Loading
NASDAQHealthcareMedical - Devices
Latest quote
$15.675
−$0.165 · -1.04%
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Latest quote
$15.675
−$0.165 · -1.04%
After-hours
$15.60
−$0.075 · -0.48%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Day range
Current $15.675
52-week range
Current $15.675
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
70
Bullish
Risk
70
High Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tandem Diabetes Care, Inc., a medical technology firm, specializes in creating, developing, and marketing solutions for individuals globally who manage insulin-dependent diabetes. At the core of its offerings is the t:slim X2 insulin delivery system, an advanced pump platform that integrates the t:slim X2 pump, a disposable 300-unit insulin cartridge, and an infusion set. Tandem further enhances this platform with innovative features like Basal-IQ and Control-IQ technology, as well as G5 Integration capabilities. The company also provides the Tandem Device Updater, enabling users to easily update their pump's software. To facilitate therapy management, Tandem offers t:connect, a web-based application that visually presents diabetes data from the pump, continuous glucose monitoring (CGM) devices, and supported blood glucose meters to patients, their caregivers, and healthcare professionals. Additionally, the Sugarmate mobile application caters specifically to insulin users with diabetes. Tandem has strategic development and commercialization partnerships with leading companies such as Dexcom, Inc. and Abbott Laboratories. Established in 2006 and headquartered in San Diego, California, the company was initially known as Phluid Inc. before rebranding as Tandem Diabetes Care, Inc. in January 2008.
Day range
Current $15.675
52-week range
Current $15.675
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.01B USD | 940.2M USD | 747.72M USD | 801.22M USD | 702.8M USD |
| Cost of goods sold | 483.89M USD | 450.63M USD | 380.03M USD | 388.23M USD | 326.58M USD |
| Gross profit | 530.85M USD | 489.57M USD | 367.69M USD | 412.99M USD | 376.22M USD |
| Research and development | 174.84M USD | 198.88M USD | 248.42M USD | 170.15M USD | 92.05M USD |
| Selling, general, and administrative | 434.13M USD | 389.82M USD | 352.5M USD | 335.68M USD | 261.51M USD |
| Operating expenses | 608.97M USD | 588.7M USD | 600.92M USD | 505.83M USD | 353.56M USD |
| Interest income | 9.09M USD | 17.99M USD | 22.86M USD | 6.06M USD | 674K USD |
| Interest expense | 7.91M USD | 7.42M USD | 9.88M USD | 6.21M USD | 6.04M USD |
| Depreciation and amortization | 17.67M USD | 16.61M USD | 15.72M USD | 14.33M USD | 13.85M USD |
| Operating income | −78.12M USD | −99.13M USD | −233.23M USD | −92.85M USD | 22.65M USD |
| Net income | −204.71M USD | −96.03M USD | −222.61M USD | −94.59M USD | 15.57M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 10, 2017 | 1:10 | — | — |
Effective Oct 10, 2017
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR65.88M0.06%102.88B USD0.06%$137.31+0.17%
Vanguard Morningstar Total Stock Market ETFVTI48.13M0.00%2.3T USD0.03%$379.56-0.39%
Vanguard Morningstar Small-Cap ETFVB34.67M0.02%185.3B USD0.03%$287.63+0.23%
iShares Russell 2000 ETFIWM28.98M0.04%77.7B USD0.19%$277.57-0.05%
Vanguard Morningstar Small-Cap Growth ETFVBK19.87M0.04%44.7B USD0.05%$340.59-0.48%
Vanguard Extended Market ETFVXF17.53M0.02%95.4B USD0.05%$233.13-0.15%
Fidelity Enhanced Small Cap ETFFESM13.54M0.21%6.41B USD0.28%$45.25+0.07%
iShares Russell 2000 Growth ETFIWO10.35M0.07%14.04B USD0.24%$353.47-0.53%iShares Core S&P Small-Cap ETFIJRVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
